Tag Archives: GSK’s

GSK’s two-drug HIV therapy shines in two big studies

Signage for GlaxoSmithKline is seen on it's offices in London, BritainGlaxoSmithKline's already fast-growing HIV drug business has received an important boost with the success of two major clinical studies testing a new two-drug treatment regimen to control the virus that causes AIDS. The approach is a departure from conventional triple drug cocktails that can cause troublesome side effects, especially among older patients who make up a growing proportion of those treated for the disease. Antiretroviral therapy has turned HIV from a death sentence into a manageable condition but patients need to stay on treatment for life, so there is a growing focus on making medication as well-tolerated as possible.



Sexual Health News Headlines – Yahoo! News

GSK’s modern HIV drug to be rolled out in Botswana

The GlaxoSmithKline building in Hounslow, west LondonLONDON (Reuters) – An HIV drug first approved less than three years is to be rolled out in Botswana as a first-line core medicine to treat newly diagnosed patients under a contract agreed between the government and ViiV Healthcare. ViiV, which is majority-owned by GlaxoSmithKline, said on Friday it was the first time Tivicay, or dolutegravir, was being made available as part of a national health program in sub-Saharan Africa. No financial details were given. Pfizer and Shionogi also hold minority stakes in ViiV. (Reporting by Ben Hirschler; editing by Jason Neely)



Sexual Health News Headlines – Yahoo! News

Manufacturing deal wins China cheap supply of GSK’s new HIV drug

A British Airways airplane flies past a signage for pharmaceutical giant GlaxoSmithKlein in LondonChina will receive cut-price supplies of GlaxoSmithKline's new HIV drug Tivicay, following a deal for Shanghai-based Desano Pharmaceuticals to become an additional manufacturer of the medicine's active ingredient. The collaboration between GSK's HIV unit ViiV Healthcare and Desano marks an improvement in the business climate for the British drugmaker, which was fined a record 3 billion yuan ($ 484 million) in September for bribing Chinese doctors. Under the agreement announced by ViiV on Thursday, Desano will manufacture the active pharmaceutical ingredient for Tivicay, or dolutegravir, to feed into the GSK/ViiV supply chain for onward sale in China and other developing countries.



Sexual Health News Headlines – Yahoo! News

GSK’s ViiV unit adds new HIV drug to AIDS patent pool

GlaxoSmithKline’s AIDS drugs business is to add one of its latest HIV medicines to a patent pool – cutting its future price for developing countries and pooling intellectual property rights. ViiV Healthcare, which is majority owned by the British drugmaker, said the agreement covered dolutegravir, a new antiretroviral medicine, for use in both adults and children with the human immunodeficiency virus (HIV) that causes AIDS. The move is a further victory for the new Medicines Patent Pool (MPP), which is trying to convince major drugmakers around the world to share rights to important medicines for developing countries with makers of cheap generic drugs.
Sexual Health News Headlines – Yahoo! News

GSK’s HIV drug beats Gilead market leader in study

LONDON (Reuters) – An experimental once-daily AIDS drug from GlaxoSmithKline and its Japanese partner Shionogi has proved better than Gilead’s market-leading Atripla in a late-stage clinical trial, increasing hopes for the product. Dolutegravir, which could reach the market late next year, belongs to a novel class of drugs known as integrase inhibitors that fight HIV/AIDS by blocking the virus causing the disease from entering cells. It should help British group GSK rejuvenate its HIV/AIDS business – an area it used to dominate but where it has fallen behind rivals, notably U.S. rival Gilead. …
Sexual Health News Headlines – Yahoo! News